NYSE · LLY
Eli Lilly and Company
$1,417.54+$43.84 (+3.19%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.22% below the high.
Loading market information…
OTC · SYNI · USD
Stock price
Quote as of Dec 30, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Synvista Therapeutics, Inc. functions as a biopharmaceutical company dedicated to creating both diagnostic tools and therapeutic drugs. Its core objective is to identify and provide treatment options for diabetic patients who are at an elevated risk of developing cardiovascular disease. The company's product portfolio includes ALT-2074, a glutathione peroxidase mimetic currently in Phase II clinical trials, which aims to treat diabetic patients with Hp2-2. Additionally, Synvista is advancing Alagebrium chloride (or alagebrium), an Advanced Glycation End-product Crosslink Breaker, also in Phase II trials, for its potential application in treating diastolic heart failure and diabetic nephropathy. Beyond its therapeutic pipeline, the firm is actively developing a diagnostic test specifically designed to detect and guide treatment for diabetic individuals prone to cardiovascular complications. Founded in 1986, the company was previously known as Alteon, Inc. and maintains its corporate headquarters in Montvale, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:45 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$1,417.54+$43.84 (+3.19%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.22% below the high.
$273.20-$2.00 (-0.73%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 3.12% below the high.
$294.89+$4.10 (+1.41%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.29% below the high.
$149.52+$3.19 (+2.18%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.72% below the high.
$406.97-$3.94 (-0.96%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.84% below the high.
$697.00-$12.18 (-1.72%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$466.01+$5.28 (+1.15%)
Amgen Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.03% below the high.
$170.68+$5.07 (+3.06%)
Gilead Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.83% below the high.
